OpenAI advances recursive AI; new startup pursues self-improving systems amid leaked experimental model names.

The Nasdaq stock exchange wants to list binary options tied to its flagship stock indexes, a move that would let traders place yes-or-no bets on the direction of major equity benchmarks like the ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

GameSpot may get a commission from retail offers. Helldivers 2 doesn't give its players much of breather before throwing another invasion or intergalactic threat at them. Players across PlayStation 5, ...

See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add The New York Times on GoogleAgrega The New York Times en Google As Donald Trump ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...